Wikipedia

A. David Smith

Anthony David Smith FMedSci (born 16 September 1938) is a British biochemist and pharmacologist. Smith has spent his entire academic career in the University of Oxford.[1][2] His research focuses on biochemical changes with disease and prevention. This includes co-founding the Oxford Project to Investigate Memory and Ageing (OPTIMA[3]). He is one of the leaders of international research to find ways to prevent dementia.[4] He is also known for his work on the anatomical neuropharmacology of the basal ganglia.

A. David Smith
Born16 September 1938 (age 86)
Alma materUniversity of Oxford
Known forIdentifying factors contributing to the development of dementia
Scientific career
FieldsPharmacology, Neuroscience, Neuropharmacology
Websitewww.pharm.ox.ac.uk/team/a-david-smith Edit this at Wikidata

Early life and education

edit

Smith was born in Kunming, China (missionary parents) and educated in Kingswood School, Bath. After 2 years as a technician at the MRC Radiobiological Research Unit, Harwell he became an undergraduate at Christ Church, University of Oxford where he graduated with a first-class honours degree in Biochemistry in 1963. He then joined the Department of Pharmacology[5] in Oxford and gained a D.Phil. in 1966. His doctoral research investigated the secretion of chemicals from the adrenal gland.[6]

Research and career

edit

After serving as Royal Society Stothert Research Fellow (1967–70), Smith was appointed University Lecturer in Pharmacology and Student (Fellow) of Christ Church in 1971. He was awarded the Gaddum Memorial Prize in 1978 for his discoveries on the release of noradrenaline through exocytosis.[7] In 1979 Smith introduced an antenatal acetylcholinesterase test for spina bifida in early pregnancy which has been used around the world.[8]

In 1984, David Smith was elected the fourth Statutory Chair of Pharmacology in the University of Oxford, and Head of Department until 2005.[9] In the same year, he was elected a Fellow of Lady Margaret Hall in Oxford where he remains an Emeritus Fellow.

David Smith co-founded the International Brain Research Organization's journal Neuroscience[10] and he served as Chief Editor from 1976 to 2001.

In 1985 Smith was appointed Founding Director of the MRC Anatomical Neuropharmacology Unit, Oxford which was associated with the Department of Pharmacology with associate director, Peter Somogyi FRS.[11]

In 1987 David Smith negotiated an agreement with E.R. Squibb & Sons Inc., which led to the donation of £20 million to the University of Oxford for a new building for the Department of Pharmacology and funding for research into brain diseases.[12]

In 1988 Smith co-founded the Oxford Project to Investigate Memory and Ageing (OPTIMA[13]), a longitudinal clinico-pathological study on more than 1,000 people to identify modifiable risk factors contributing to dementia, which continued until 2015.[14]

 
Portrait of A. David Smith (2005) by Beth Marsden

In 1998, OPTIMA discovered that elevated homocysteine and low levels of B vitamins are important risk factors for the development of Alzheimer's and vascular dementia.[15] This finding led to the VITACOG clinical trial to investigate whether lowering plasma homocysteine concentrations through high doses of supplementary B vitamins (folic acid, vitamins B6 and B12) over two years could slow the rate of losing brain tissue in elderly subjects with mild cognitive impairment, a precursor of dementia.[16] The results showed that the accelerated rate of brain atrophy in elderly with mild cognitive impairment can be significantly reduced in over half of cases through treatment with homocysteine-lowering B vitamins in subjects with a good omega-3 fatty acids status. In the same subjects, cognitive decline was slowed.

In 2000, Smith was appointed Deputy-Head (Vice-Dean) for 5 years to the newly established Medical Sciences Division[17] in the University of Oxford. In the same year he was elected Fellow of the Academy of Medical Sciences UK.[18]

From 1997 to 2002 Smith was the first Chair of the Scientific Advisory Board of Alzheimer's Research UK. In 2006, Alzheimer's Research UK appointed David Smith as their first Honorary Research Fellow. The David Smith Lectures in Anatomical Neuropharmacology[19] were established in 2008 as part of the 25th anniversary of the MRC Anatomical Neuropharmacology Unit.[20] A portrait of David Smith by Beth Marsden[21] (2005) hangs in the entrance lobby of the Department of Pharmacology.

Awards and honours

edit

Selected publications (from over 400)

edit
  • 1959 Smith, A.D., Ashwood-Smith, M. J.; Lowman, D. Radioprotective action of methoxamine. Nature 1959: 184, 1729-1730.[24]
  • 1967 Schneider, F.H., Smith. A.D .and Winkler H. Secretion from the adrenal medulla: biochemical evidence for exocytosis. Brit. J. Pharmac. Chemother., 31; 94-104[25]
  • Blaschko, H., Comline, R. S., Schneider, F. H., Silver, M., Smith, A. D. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 1967: 215, 58-59.[26]
  • 1971 Smith, A. D. Secretion of proteins (chromogranin A and dopamine beta-hydroxylase) from a sympathetic neuron. Phil. Trans. Roy. Soc. Lond. B 1971: 261, 363-371.[27]
  • Smith, A.D. Some implications of the neuron as a secreting cell. Phil. Trans. Roy. Soc. Lond. B, 261;423-37.[28]
  • 1976 Chubb, I. W.; Goodman, S.; Smith, A. D. Is acetylcholinesterase secreted from central neurons into cerebrospinal fluid? Neuroscience 1, 57-62.[29]
  • 1979 Smith, A.D, Wald, N.J, H S Cuckle, H.S., Stirrat,G.M., M Bobrow, M. and H Lagercrantz, H. Amniotic-fluid acetylcholinesterase as a possible diagnostic test for neural-tube defects in early pregnancy. Lancet 313: 685-688.[30]
  • Somogyi, P., Hodgson, A. J., Smith, A. D.  An approach to tracing neuron networks in the cerebral cortex and basal ganglia. Combination of Golgi staining, retrograde transport of horseradish peroxidase and anterograde degeneration of synaptic boutons in the same material. Neuroscience 4, 1805-1852.[31]
  • 1990 Smith, A. D. and Bolam, J. P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. Trends Neurosci.13, 259-265.[32]
  • 1992 Jobst, K. A., Smith, A. D, Szatmari, M., Molyneux, A., Esiri, M. M., King, E., Smith, A., Jaskowski, A., McDonald, B., Wald, N. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 340, 1179-1183.[33]
  • 2010 Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H. (2010) Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One.  5(9): e12244.[34]
  • 2013 Douaud G., Refsum, H., de Jager, C.A., Jacoby, R., Nichols, T.E., Smith, S.M., Smith, A.D.  Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A, 110, 9523 – 9528.[35]
  • 2014 Smith, A.D. and Yaffe K. Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts. J Alzheimers Dis, 38, 699 - 703.[36]
  • 2016 Smith, A.D and Refsum H. Homocysteine, B Vitamins, and Cognitive Impairment. Annu Rev Nutr, 36, 211 – 239[37]
  • 2017 Smith, A.D. and Refsum H. Dementia Prevention by Disease-Modification through Nutrition. J Prev Alzheimers Dis, 4, 138 – 139[38]
  • 2018 Smith, A.D., Refsum, H., Bottiglieri T., Fenech, M., Hooshmand, B., McCaddon, A., Miller, J.W., Rosenberg, I.H. and Obeid, R. Homocysteine and Dementia: An International Consensus Statement. J Alzheimers Dis, 62, 561 – 570.[39]
  • Smith A.D., Warren M.J. and Refsum, H. Vitamin B12. Adv Food Nutr Res. 83: 215-279.[40]
  • 2021 Smith A.D. and Refsum, H. Homocysteine – from disease biomarker to disease prevention. J. Intern. Med. 290; 826-854[41]
  • 2023 Grande G.,Hooshmand B., Vetrano D.L.,Smith D. A., Refsum H.,Fratiglioni L., Ljungman, P., Wu J., Bellavia A., Eneroth K., Bellander T. and Rizzuto D. Association of long-term exposure to air pollution and dementia risk: The role of homocysteine, methionine, and cardiovascular burden. Neurology; 101, 12, e1231-e1240.[42]
  • Zhang, Y., Chen S.D., Deng Y. T., You J., He X.Y., Wu X.R., Wu B.S., Yang L., Zhang Y.R., Kuo K., Feng J.F., Cheng W., Suckling J., Smith A.D. and Yu J.T. Identifying modifiable factors and their joint effect on dementia risk in the UK biobank. Nat Hum Behav 7, 1185-1195.[43]

Personal life

edit

Smith has two sons and one daughter. He is interested in music and art. In 1981 he and his wife organised the first visit of the Berlin Philharmonic Orchestra to Oxford for a concert with Herbert von Karajan in the Sheldonian Theatre, broadcast by the BBC.[44] Since 2022, Smith has written reviews on art history including on Scandinavian artists.[45][46] Smith lives in Sweden.

References

edit
  1. ^ "A David Smith". www.pharm.ox.ac.uk. Retrieved 2024-09-10.
  2. ^ "Smith, Prof. (Anthony) David, (born 16 Sept. 1938), Professor of Pharmacology, 1984–2005, now Emeritus, and Deputy Head, Division of Medical Sciences, 2000–05, University of Oxford; Director, Oxford Project to Investigate Memory and Ageing, 1988–2008, now Founding Director; Fellow, Lady Margaret Hall, Oxford, 1984–2005, now Emeritus Fellow". WHO'S WHO & WHO WAS WHO. 2007. doi:10.1093/ww/9780199540884.013.u35248. Retrieved 2024-09-10.
  3. ^ "OPTIMA".
  4. ^ Smith, A. David; Yaffe, Kristine (2014). "Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts". Journal of Alzheimer's Disease: JAD. 38 (4): 699–703. doi:10.3233/JAD-132372. ISSN 1875-8908. PMID 24326609.
  5. ^ "Homepage". www.pharm.ox.ac.uk.
  6. ^ Schneider, F H; Smith, A D; Winkler, H (September 1967). "Secretion from the adrenal medulla: biochemical evidence for exocytosis". British Journal of Pharmacology and Chemotherapy. 31 (1): 94–104. doi:10.1111/j.1476-5381.1967.tb01980.x. ISSN 0366-0826. PMC 1557278. PMID 6058830.
  7. ^ "Gaddum International Lecture Past Winners". British Pharmacological Society (PDF). 2018.
  8. ^ Smith, A. D.; Wald, N. J.; Cuckle, H. S.; Stirrat, G. M.; Bobrow, M.; Lagercrantz, H. (1979-03-31). "Amniotic-fluid acetylcholinesterase as a possible diagnostic test for neural-tube defects in early pregnancy". Lancet. 1 (8118): 685–688. doi:10.1016/s0140-6736(79)91144-9. ISSN 0140-6736. PMID 85932.
  9. ^ "Growing up as a Pharmacologist - during more than half a century in the Department". podcasts.ox.ac.uk. Retrieved 2024-09-10.
  10. ^ "Home Page: Neuroscience".
  11. ^ "Unit History | Anatomical Neuropharmacology Unit". mrcanu.pharm.ox.ac.uk. Retrieved 2024-09-10.
  12. ^ "Privatised Pharmacology". The Lancet. 330 (8573): 1439–1440. December 1987. doi:10.1016/s0140-6736(87)91135-4. ISSN 0140-6736.
  13. ^ Smith, A. David (December 2009). "Dispelling myths about Alzheimer's disease" (PDF). Oxford Medicine. University of Oxford.
  14. ^ "David Smith on Dementia". podcasts.ox.ac.uk. Retrieved 2024-09-10.
  15. ^ Clarke, R.; Smith, A. D.; Jobst, K. A.; Refsum, H.; Sutton, L.; Ueland, P. M. (November 1998). "Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease". Archives of Neurology. 55 (11): 1449–1455. doi:10.1001/archneur.55.11.1449. ISSN 0003-9942. PMID 9823829.
  16. ^ Research, F. A. B. "FAB: OPTIMA - VITACOG: Clinical Trial of B vitamins for prevention of age-related cognitive decline and dementia". library.fabresearch.org. Retrieved 2024-09-10.
  17. ^ "Medical Sciences Division". www.medsci.ox.ac.uk.
  18. ^ "Professor A. David Smith". acmedsci.ac.uk. Retrieved 2024-09-10.
  19. ^ "David Smith Lecture".
  20. ^ "David Smith Lecture". www.pharm.ox.ac.uk. Retrieved 2024-09-10.
  21. ^ "Beth Marsden. Painter". Beth Marsden. Painter.
  22. ^ "David Smith".
  23. ^ "International Society for Orthomolecular Medicine". ISOM.
  24. ^ SMITH AD; ASHWOOD-SMITH MJ; LOWMAN D (1959). "Radioprotective action of methoxamine". Nature. 184(Suppl22) (4700): 1729–1730. Bibcode:1959Natur.184.1729S. doi:10.1038/1841729a0. PMID 13854851.
  25. ^ Schneider, F. H.; Smith, A. D.; Winkler, H. (1967). "Secretion from the adrenal medulla: Biochemical evidence for exocytosis". British Journal of Pharmacology and Chemotherapy. 31 (1): 94–104. doi:10.1111/j.1476-5381.1967.tb01980.x. PMC 1557278. PMID 6058830.
  26. ^ Blaschko, H.; Comline, R. S.; Schneider, F. H.; Silver, M.; Smith, A. D. (1967). "Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation". Nature. 215 (5096): 58–59. Bibcode:1967Natur.215...58B. doi:10.1038/215058a0. PMID 6053402.
  27. ^ Smith, A. D. (1971). "Secretion of proteins (Chromogranin a and dopamine -hydroxylase) from a sympathetic neuron". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 261 (839): 363–370. doi:10.1098/rstb.1971.0066. PMID 4108422.
  28. ^ Smith, A. D. (1971). "Summing up: Some implications of the neuron as a secreting cell". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 261 (839): 423–437. Bibcode:1971RSPTB.261..423S. doi:10.1098/rstb.1971.0076. PMID 4400398.
  29. ^ Chubb, I. W.; Goodman, S.; Smith, A. D. (1976). "Is acetylcholinesterase secreted from central neurons into the cerebral fluid?". Neuroscience. 1 (1): 57–62. doi:10.1016/0306-4522(76)90048-8. PMID 980251.
  30. ^ Smith, A. D.; Wald, N. J.; Cuckle, H. S.; Stirrat, G. M.; Bobrow, M.; Lagercrantz, H. (1979). "Amniotic-fluid acetylcholinesterase as a possible diagnostic test for neural-tube defects in early pregnancy". Lancet. 1 (8118): 685–688. doi:10.1016/s0140-6736(79)91144-9. PMID 85932.
  31. ^ Somogyi, P.; Hodgson, A. J.; Smith, A. D. (1979). "An approach to tracing neuron networks in the cerebral cortex and basal ganglia. Combination of Golgi staining, retrograde transport of horseradish peroxidase and anterograde degeneration of synaptic boutons in the same material". Neuroscience. 4 (12): 1805–1852. doi:10.1016/0306-4522(79)90059-9. PMID 93712.
  32. ^ Smith, A. D.; Bolam, J. P. (1990). "The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones". Trends in Neurosciences. 13 (7): 259–265. doi:10.1016/0166-2236(90)90106-k. PMID 1695400.
  33. ^ Jobst, K. A.; Smith, A. D.; Szatmari, M.; Molyneux, A.; Esiri, M. E.; King, E.; Smith, A.; Jaskowski, A.; McDonald, B.; Wald, N. (1992). "Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography". Lancet. 340 (8829): 1179–1183. doi:10.1016/0140-6736(92)92890-r. PMID 1359259.
  34. ^ Smith, A. D.; Smith, S. M.; De Jager, C. A.; Whitbread, P.; Johnston, C.; Agacinski, G.; Oulhaj, A.; Bradley, K. M.; Jacoby, R.; Refsum, H. (2010). "Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial". PLOS ONE. 5 (9): e12244. Bibcode:2010PLoSO...512244S. doi:10.1371/journal.pone.0012244. PMC 2935890. PMID 20838622.
  35. ^ Douaud, G.; Refsum, H.; De Jager, C. A.; Jacoby, R.; Nichols, T. E.; Smith, S. M.; Smith, A. D. (2013). "Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment". Proceedings of the National Academy of Sciences of the United States of America. 110 (23): 9523–9528. Bibcode:2013PNAS..110.9523D. doi:10.1073/pnas.1301816110. PMC 3677457. PMID 23690582.
  36. ^ Smith, A. D.; Yaffe, K. (2014). "Dementia (Including Alzheimer's disease) can be prevented: Statement supported by international experts". Journal of Alzheimer's Disease. 38 (4): 699–703. doi:10.3233/JAD-132372. PMID 24326609.
  37. ^ Smith, A. D.; Refsum, H. (2016). "Homocysteine, B Vitamins, and Cognitive Impairment". Annual Review of Nutrition. 36: 211–239. doi:10.1146/annurev-nutr-071715-050947. PMID 27431367.
  38. ^ Smith, A. D.; Refsum, H. (2017). "Dementia Prevention by Disease-Modification through Nutrition". The Journal of Prevention of Alzheimer's Disease. 4 (3): 138–139. PMID 29182704.
  39. ^ Smith, A. D.; Refsum, H.; Bottiglieri, T.; Fenech, M.; Hooshmand, B.; McCaddon, A.; Miller, J. W.; Rosenberg, I. H.; Obeid, R. (2018). "Homocysteine and Dementia: An International Consensus Statement". Journal of Alzheimer's Disease. 62 (2): 561–570. doi:10.3233/JAD-171042. PMC 5836397. PMID 29480200.
  40. ^ Smith, A. D.; Warren, M. J.; Refsum, H. (2018). "Vitamin B(12)". Advances in Food and Nutrition Research. 83: 215–279. doi:10.1016/bs.afnr.2017.11.005. ISBN 978-0-12-811803-0. PMID 29477223.
  41. ^ Smith, A. D.; Refsum, H. (2021). "Homocysteine - from disease biomarker to disease prevention". Journal of Internal Medicine. 290 (4): 826–854. doi:10.1111/joim.13279. PMID 33660358.
  42. ^ Grande, G.; Hooshmand, B.; Vetrano, D. L.; Smith, D. A.; Refsum, H.; Fratiglioni, L.; Ljungman, P.; Wu, J.; Bellavia, A.; Eneroth, K.; Bellander, T.; Rizzuto, D. (2023). "Association of Long-term Exposure to Air Pollution and Dementia Risk: The Role of Homocysteine, Methionine, and Cardiovascular Burden". Neurology. 101 (12): e1231–e1240. doi:10.1212/WNL.0000000000207656. PMC 10516275. PMID 37442622.
  43. ^ Zhang, Y.; Chen, S. D.; Deng, Y. T.; You, J.; He, X. Y.; Wu, X. R.; Wu, B. S.; Yang, L.; Zhang, Y. R.; Kuo, K.; Feng, J. F.; Cheng, W.; Suckling, J.; David Smith, A.; Yu, J. T. (2023). "Identifying modifiable factors and their joint effect on dementia risk in the UK Biobank". Nature Human Behaviour. 7 (7): 1185–1195. doi:10.1038/s41562-023-01585-x. PMID 37024724.
  44. ^ "BBC Programme Index". genome.ch.bbc.co.uk. 1981-05-28. Retrieved 2024-09-10.
  45. ^ "Smith, David (2022). Bertha Wegmann: Painting in Many Languages. . Burlington Magazine 164: 803-5". www.burlington.org.uk. Retrieved 2024-09-10.
  46. ^ Smith, David (2023). "Albert Edelfelt: Modern Artist Life in Fin-de-Siècle Europe". Nineteenth-Century Art Worldwide. 22 (1). doi:10.29411/ncaw.2023.22.1.19.
Retrieved from "https://en.wiki.x.io/w/index.php?title=A._David_Smith&oldid=1254406120"